document.write('<div class="rss_box">');
document.write('<ul class="rss_items">');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/kaletra/2010/08/majority-of-hiv-positive-people-on-antiretroviral-therapy-may-have-reduced-bone-density?fromrss=1"  target="feed">Majority of HIV Positive People on Antiretroviral Therapy May Have Reduced Bone Density</a>');
document.write('<br /><p>SUMMARY: About half of people with HIV taking antiretroviral therapy in a Spanish study had low bone mineral density, and another quarter had more severe bone loss, researchers reported at the XVIII International AIDS Conference last month in Vienna.</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/kaletra/2010/08/switching-from-boosted-protease-inhibitor-to-raltegravir-maintains?fromrss=1"  target="feed">Switching from Boosted Protease Inhibitor to Raltegravir Maintains...</a>');
document.write('<br /><p>SUMMARY: Switching from a ritonavir-boosted protease inhibitor to the integrase inhibitor raltegravir can maintain viral load at an undetectable level for most patients, but those with pre-existing nucleoside/nucleoside reverse transcriptase inhibitors resistance mutations have an increased risk of virological failure if the drug is taken only ...</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/kaletra/2010/07/studies-explore-nrti-sparing-antiretroviral-regimens-using-new-drug-classes?fromrss=1"  target="feed">Studies Explore NRTI-sparing Antiretroviral Regimens Using New Drug Classes</a>');
document.write('<br /><p>SUMMARY: Novel antiretroviral therapy regimens that combine boosted protease inhibitors with a new integrase inhibitor or CCR5 antagonist, while omitting nucleoside/nucleotide reverse transcriptase inhibitors , demonstrated good efficacy and tolerability in treatment-naive patients, researchers reported at the XVIII International AIDS Conference ...</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/kaletra/2010/07/does-nevirapine-improve-response-to-interferon-based-therapy-in-hiv-hcv-coinfected-patients?fromrss=1"  target="feed">Does Nevirapine Improve Response to Interferon-based Therapy in HIV/HCV Coinfected Patients?</a>');
document.write('<br /><p>SUMMARY: Use of an antiretroviral therapy regimen containing nevirapine was associated with a higher rate of sustained virological response to interferon-based therapy among HIV/HCV coinfected patients, according to a study presented last week at the XVIII International AIDS Conference in Vienna.</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/kaletra/2010/07/nrti-sparing-regimen-of-lopinavir-ritonavir-plus-raltegravir-works-as?fromrss=1"  target="feed">NRTI-sparing Regimen of Lopinavir/ritonavir plus Raltegravir Works as ...</a>');
document.write('<br /><p>SUMMARY: An antiretroviral therapy regimen consisting of the protease inhibitor lopinavir/ritonavir plus the integrase inhibitor raltegravir suppressed HIV viral load as well as a traditional 3-drug highly active ART combination, while avoiding potential adverse side effects of nucleoside/nucleotide reverse transcriptase inhibitors , according to ...</p>');
document.write('</li>');
document.write('</ul></div>');
document.close();